@article{MaucherSrourDanhofetal.2021,
  author    = {Maucher, Marius and Srour, Micha and Danhof, Sophia and Einsele, Hermann and Hudecek, Michael and Yakoub-Agha, Ibrahim},
  title     = {Current limitations and perspectives of chimeric antigen receptor-T-cells in acute myeloid leukemia},
  series = {Cancers},
  volume    = {13},
  journal   = {Cancers},
  number    = {24},
  issn      = {2072-6694},
  doi       = {10.3390/cancers13246157},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-252180},
  year      = {2021},
  abstract  = {Adoptive transfer of gene-engineered chimeric antigen receptor (CAR)-T-cells has emerged as a powerful immunotherapy for combating hematologic cancers. Several target antigens that are prevalently expressed on AML cells have undergone evaluation in preclinical CAR-T-cell testing. Attributes of an 'ideal' target antigen for CAR-T-cell therapy in AML include high-level expression on leukemic blasts and leukemic stem cells (LSCs), and absence on healthy tissues, normal hematopoietic stem and progenitor cells (HSPCs). In contrast to other blood cancer types, where CAR-T therapies are being similarly studied, only a rather small number of AML patients has received CAR-T-cell treatment in clinical trials, resulting in limited clinical experience for this therapeutic approach in AML. For curative AML treatment, abrogation of bulk blasts and LSCs is mandatory with the need for hematopoietic recovery after CAR-T administration. Herein, we provide a critical review of the current pipeline of candidate target antigens and corresponding CAR-T-cell products in AML, assess challenges for clinical translation and implementation in routine clinical practice, as well as perspectives for overcoming them.},
  language  = {en}
}
@article{MaulanaKromidasWallstabeetal.2021,
  author    = {Maulana, Tengku Ibrahim and Kromidas, Elena and Wallstabe, Lars and Cipriano, Madalena and Alb, Miriam and Zaupa, C{\´e}cile and Hudecek, Michael and Fogal, Birgit and Loskill, Peter},
  title     = {Immunocompetent cancer-on-chip models to assess immuno-oncology therapy},
  series = {Advanced Drug Delivery Reviews},
  volume    = {173},
  journal   = {Advanced Drug Delivery Reviews},
  doi       = {10.1016/j.addr.2021.03.015},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-370493},
  pages     = {281-305},
  year      = {2021},
  abstract  = {The advances in cancer immunotherapy come with several obstacles, limiting its widespread use and benefits so far only to a small subset of patients. One of the underlying challenges remains to be the lack of representative nonclinical models that translate to human immunity and are able to predict clinical efficacy and safety outcomes. In recent years, immunocompetent Cancer-on-Chip models emerge as an alternative human-based platform that enables the integration and manipulation of complex tumor microenvironment. In this review, we discuss novel opportunities offered by Cancer-on-Chip models to advance (mechanistic) immuno-oncology research, ranging from design flexibility to multimodal analysis approaches. We then exemplify their (potential) applications for the research and development of adoptive cell therapy, immune checkpoint therapy, cytokine therapy, oncolytic virus, and cancer vaccines.},
  language  = {en}
}